Orient Europharma Co., Ltd.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease

First Posted Date
2023-07-03
Last Posted Date
2023-07-03
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
100
Registration Number
NCT05926713
Locations
🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

Phase 1
Active, not recruiting
Conditions
Osteoarthritis, Knee
Interventions
Drug: 2ccPA
Drug: Placebo
First Posted Date
2023-04-11
Last Posted Date
2024-03-21
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
136
Registration Number
NCT05807529
Locations
🇨🇳

Tri-Service General Hospital, Taipei, Taiwan

Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Liver Dysfunction
Interventions
Drug: Mitiglinide
First Posted Date
2020-04-16
Last Posted Date
2021-04-30
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
16
Registration Number
NCT04349696
Locations
🇨🇳

Chiayi Chang Gung Memorial Hospital, Chiayi City, Taiwan

🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Evaluate the Effect of Dietary Supplement on Muscle Mass and Physical Performance for Over 50 Years Old People

First Posted Date
2020-01-18
Last Posted Date
2021-04-30
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
80
Registration Number
NCT04229407
Locations
🇨🇳

Veteran General Hospital-Taipei, Taipei, Taiwan

2ccPA Study in Patients With Symptomatic Knee Osteoarthritis

Phase 1
Completed
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Drug: 2ccPA
Drug: placebo
First Posted Date
2020-01-18
Last Posted Date
2021-04-30
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
40
Registration Number
NCT04229394
Locations
🇨🇳

Tri-Service General Hospital, Taipei, Taiwan

🇨🇳

Mackay Memorial Hospital, Taipei, Taiwan

🇨🇳

Kaohsiung Chang Gung Memorial Hospital, Taipei, Taiwan

and more 2 locations

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

First Posted Date
2016-06-29
Last Posted Date
2021-04-30
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
4
Registration Number
NCT02817113
Locations
🇨🇳

Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan

🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Phase 3
Completed
Conditions
Pancreatic Neoplasms
Interventions
Drug: NC-6004
Drug: Gemcitabine
First Posted Date
2014-01-23
Last Posted Date
2020-04-15
Lead Sponsor
Orient Europharma Co., Ltd.
Target Recruit Count
310
Registration Number
NCT02043288
Locations
🇰🇷

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

🇯🇵

Chiba Cancer Center, Chiba, Japan

🇰🇷

Korea University Guro Hospital (KUGH), Seoul, Korea, Republic of

and more 40 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy